Seeking Alpha

QualityStocks'  Instablog

Send Message
QualityStocks ( assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • VentriPoint Diagnostics Ltd. (VPTDF) Business Model Designed For Rich Recurring Revenue 0 comments
    Aug 1, 2013 6:07 PM | about stocks: VPTDF

    The VentriPoint business model parallels that of GE Healthcare, Phillips, Siemens, and Toshiba, with initial technology-based product sales acting as a platform for a range of recurring revenues. VentriPoint's innovative ultrasound based medical imaging analysis technology provides an easy-to-use and highly cost-effective alternative to MRI and other high-end medical diagnostic tools and procedures. It's of special value for right heart analysis, where a standard ultrasound approach is ineffective, and for pediatric patients where elaborate MRI scanning may be difficult to tolerate. It's a technology of widening application, designed to save both time and money, and it's finding a home in a growing number of hospitals around the world.

    The system's capital purchase list price of $100,000 per unit sets up a base for the following recurring revenues:

    •$10,000 per year per unit - Access to databases, software, and hardware maintenance

    •$20,000 - $50,000 per year per unit - Software upgrades, access to new databases and additional training

    •$5,000 - $10,000 per year per unit - Training services and certification, with recertification required if you have not used the software for 3 months

    For smaller clinics, and as applications increase, the move will be to a per-use revenue model.

    Sales projections for year-end 2013 total $3 to $5 million, including recurring revenue from earlier installations, for new applications, support, maintenance, and training, with projections for 2014 totaling $10 to $15 million.

    The company targets a large market opportunity, representing a well described unmet clinical need, with gross margins of 80%. The technology is patented and proprietary, with excellent clinical validation by respected experts. It already holds Canadian and European regulatory approvals, with FDA processing underway.

    For more information on VentriPoint's leading-edge cardiac diagnostic technology, visit

    Please see disclaimer on the QualityStocks website:

    Stocks: VPTDF
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.